Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 2/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | NPC1 | O15118 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.36 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.36 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4337459 | 0.83 | RAB9A (0.54) | RAB9AKDM4ENPC1SMN1; SMN2OPRM1 | |
| SCHEMBL29004578 | 0.83 | RAB9A (0.54) | RAB9AKDM4ENPC1SMN1; SMN2OPRM1 | |
| SCHEMBL4337454 | 0.83 | RAB9A (0.54) | RAB9AKDM4ENPC1SMN1; SMN2OPRM1 | |
| SCHEMBL29004577 | 0.83 | RAB9A (0.54) | RAB9AKDM4ENPC1SMN1; SMN2OPRM1 | |
| SCHEMBL13614205 | 0.83 | RAB9A (0.54) | RAB9AKDM4ENPC1SMN1; SMN2OPRM1 | |
| SCHEMBL4617880 | 0.83 | RAB9A (0.54) | RAB9AKDM4ENPC1SMN1; SMN2OPRM1 | |
| SCHEMBL10071672 | 0.83 | RAB9A (0.54) | RAB9AKDM4ENPC1SMN1; SMN2OPRM1 | |
| SCHEMBL4338815 | 0.80 | RAB9A (0.47) | RAB9AKDM4ENPC1SMN1; SMN2OPRM1 | |
| SCHEMBL3827791 | 0.80 | RAB9A (0.55) | RAB9AKDM4ENPC1SMN1; SMN2CHRNA7 | |
| SCHEMBL11215847 | 0.79 | RAB9A (0.53) | RAB9AKDM4ENPC1SMN1; SMN2CHRNA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2311820-A1 | Process for the purification of latanoprost by HPLC | Resolution Chemicals Limited (GB) | 2011-04-20 | — | — | EP | disclosed |
| US-7498458-B2 | Process for the preparation of prostaglandins and analogues thereof | RESOLUTION CHEMICALS LIMITED (GB) | 2009-03-03 | — | — | US | disclosed |
| US-20050261374-A1 | Process for the preparation of prostaglandins and analogues thereof | RESOLUTION CHEMICALS LIMITED | 2005-11-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050261374-A1 | Process for the preparation of prostaglandins and analogues thereof | PTGIS, PTGES, PTGES2 | RAB9A 3497/4885KDM4E 4075/4885NPC1 3399/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.